Primary Hyperoxaluria

Promising results for nedosiran in primary hyperoxaluria presented during Kidney Week 2023

Nedosiran, an RNA interference therapy, has shown promising results in treating primary hyperoxaluria (PH), a rare genetic disorder, according to data presented at Kidney Week 2023 Annual Meeting. The 30-month interim analysis of the PHYOX3 study indicates that nedosiran was well-tolerated in patients with PH1 and resulted in a sustained...